MondegarAI
Pivotal bioVenture Partners Investment Advisor LLC

Q1 2025 · 13F-HR

Pivotal bioVenture Partners Investment Advisor LLCholdings as filed

Filed 2025-05-14 · accession 0001012975-25-000233

$123.6M
Reported value
11
Positions
2025-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
H5870P102OCSOCULIS HOLDING AG$43.8M35.4%2,300,774CommonSHARED
03969K108ARQTARCUTIS BIOTHERAPEUTICS INC$33.2M26.8%2,120,508CommonSHARED
92243G108PCVXVAXCYTE INC$26.8M21.7%710,734CommonSHARED
98937L105ZBIOZENAS BIOPHARMA INC$5.8M4.71%736,645CommonSHARED
45790W108INOZYME PHARMA INC$4.1M3.31%4,494,851CommonSHARED
75629V104RXRXRECURSION PHARMACEUTICALS IN$3.2M2.55%595,518CommonSHARED
09077V100BIOABIOAGE LABS INC$2.5M1.99%653,374CommonSHARED
75120L100RALLYBIO CORP$1.6M1.26%2,404,644CommonSHARED
92673K108VIGLVIGIL NEUROSCIENCE INC$997,8590.81%560,595CommonSHARED
449778109IOBTQIO BIOTECH INC$941,9750.76%864,197CommonSHARED
097702104BOLT1EURBOLT BIOTHERAPEUTICS INC$756,5870.61%1,891,467CommonSHARED

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.